Fulcrum’s Board of Directors is composed of accomplished biopharma leaders who bring their experience in science, drug development, commercialization and strategy to our efforts to develop novel medicines.
Mark Levin is a co-founder of Third Rock Ventures and an industry leader with 40 years of experience, including more than 30 years launching and building biotechnology companies. At Third Rock, Mark focuses on the formation and development of business strategy for the firm’s portfolio companies, as well as actively identifying and evaluating new investments. Prior to becoming involved in the creation of Fulcrum, Mark played significant roles in launching and building a number of the firm’s portfolio companies, including Voyager Therapeutics, Corvia Medical (previously DC Devices), NinePoint Medical, Eleven Biotherapeutics, Foundation Medicine, Constellation Pharmaceuticals and Warp Drive Bio. Before founding Third Rock, Mark was co-founder of Mayfield Fund's life sciences effort, where he was also the founding chief executive officer of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. Mark served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Lilly and Genentech. Mark holds an M.S. in chemical and biochemical engineering from Washington University.
James J. Collins, Ph.D.
Dr. James Collins is the Termeer Professor of Medical Engineering and Science in the Institute for Medical Engineering and Science and the Department of Biological Engineering at the Massachusetts Institute of Technology, and is also affiliated with the Broad Institute and the Wyss Institute. He is a renowned expert in synthetic biology and systems biology, and their applications in biotechnology and medicine. He has received numerous awards, including a Rhodes Scholarship, a MacArthur Fellowship, and a National Institutes of Health (NIH) Director’s Pioneer Award. Dr. Collins is an elected member of the National Academy of Sciences, the National Academy of Engineering, the National Academy of Medicine, and the American Academy of Arts and Sciences; and is a charter fellow of the National Academy of Inventors.
Alan Ezekowitz, MBChB, D.Phil.
Dr. Alan Ezekowitz is President and CEO of Abide Therapeutics, a company he co-founded in 2011. Formerly, he was the Senior Vice President and Franchise Head for disease areas including bone, respiratory, immunology, endocrine and dermatology at Merck Research Laboratories. Prior to Merck, Dr. Ezekowitz was the Charles Wilder Professor of Pediatrics at the Harvard Medical School and served as the Chief of Pediatric Services at the Mass General Hospital for Children and the Partners Healthcare System. Additionally, he directed the Laboratory of Developmental Immunology at Massachusetts General Hospital. Dr. Ezekowitz is a leader in the field of developmental immunology and has 150 publications. He is a member of the American Society of Clinical Investigation, a Fellow of the American Association for the Advancement of Science, and has served on multiple NIH subcommittees.
Jim Geraghty joined Third Rock Ventures as an entrepreneur-in-residence in 2013 and focuses on creating companies dedicated to improving the lives of patients with rare genetic diseases and supporting existing portfolio companies in the rare disease space, such as Fulcrum. Jim is an industry leader with 30 years of strategic and leadership experience, including more than 20 years developing and commercializing therapies for rare diseases. He has taken an active leadership role as board member and former interim CBO of Voyager Therapeutics. Prior to Third Rock, Jim served as senior vice president, North America strategy and business development at Sanofi. Before Sanofi, Jim spent 20 years at Genzyme, where his roles included senior vice president of international development, president of Genzyme Europe and general manager of Genzyme's cardiovascular business. He also served as chairman and chief executive officer of GTC Biotherapeutics (formerly Genzyme Transgenics), which he founded and took public. Jim oversaw Genzyme's Humanitarian Assistance for Neglected Diseases program, under which the company supported innovative therapeutic programs on a non-commercial basis. He is chairman of Idera Pharmaceuticals, a member of the Joslin Diabetes Center board of trustees and serves on the board of BIO Ventures for Global Health. A graduate of the Yale Law School, Jim also holds a master’s degree from the University of Pennsylvania and a bachelor’s degree from Georgetown University.
Robert J. Gould, Ph.D.
President and Chief Executive Officer, Board Member
Robert Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at the Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of president, licensing and external research. Throughout his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a B.A. from Spring Arbor College and a Ph.D. from the University of Iowa and completed postdoctoral studies at the Johns Hopkins University.